Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Am Heart J. 2020 Sep;227:56-63. doi: 10.1016/j.ahj.2020.06.002. Epub 2020 Jun 6.
The goal of the global congestive heart failure (G-CHF) registry is to collect comparative international data on heart failure characteristics, management, and outcomes and to better understand the determinants that impact the clinical course of heart failure. METHODS: G-CHF is a multicenter, prospective cohort study of adult patients with a new or prior clinical diagnosis of heart failure. We have enrolled 23,047 participants from 257 centers in 40 countries from 8 major geographic regions of the world, with recruitment ongoing. Approximately 4,000 participants will also participate in substudies to assess frailty, comorbidity, diet, barriers to care, biomarkers, and planned detailed echocardiographic analyses. Follow-up is planned for a period of 5 years. The primary outcome is cause-specific mortality. Key secondary outcomes include hospitalizations, quality of life, and major cardiovascular and noncardiovascular outcomes. A total of 31.9% of participants were enrolled as inpatients. Thus far, mean age of the cohort at baseline is 63.1 years, and 60.8% are male. Participants most commonly have heart failure with reduced ejection fraction (53.6%) followed by preserved ejection fraction (24.2%) and midrange ejection fraction (20.6%). The most common causes of heart failure are ischemic (37.8%) followed by hypertensive (20.0%), idiopathic (15.1%), and valvular disease (8.8%). CONCLUSION: G-CHF will provide a greater understanding of the characteristics of the global heart failure population, variations in its management, clinical outcomes, and what continues to impact morbidity and mortality in this high-risk population.
全球充血性心力衰竭(G-CHF)注册研究的目的是收集心力衰竭特征、管理和结局的国际比较数据,更好地了解影响心力衰竭临床进程的决定因素。
G-CHF 是一项多中心、前瞻性队列研究,纳入了 23047 例来自全球 8 个主要地理区域的 40 个国家的 257 个中心的新发或既往临床诊断为心力衰竭的成年患者。目前仍在招募患者,预计将有大约 4000 名患者参与亚研究,以评估虚弱、合并症、饮食、治疗障碍、生物标志物和计划进行的详细超声心动图分析。预计随访时间为 5 年。主要结局是病因特异性死亡率。关键次要结局包括住院、生活质量以及主要心血管和非心血管结局。共有 31.9%的参与者为住院患者。迄今为止,队列患者的基线平均年龄为 63.1 岁,60.8%为男性。患者最常见的心力衰竭类型为射血分数降低型心力衰竭(53.6%),其次为射血分数保留型心力衰竭(24.2%)和射血分数中间值型心力衰竭(20.6%)。心力衰竭最常见的病因是缺血性(37.8%),其次是高血压性(20.0%)、特发性(15.1%)和瓣膜性疾病(8.8%)。
G-CHF 将更深入地了解全球心力衰竭患者人群的特征、管理方式的差异、临床结局以及哪些因素持续影响该高危人群的发病率和死亡率。